News | May 21, 2007

Patent Applications Expanded for Laser-Based Ablation Device

May 23, 2007 — MedicalCV Inc. has announced that the United States Patent and Trademark Office ("USPTO") has issued three additional Notices of Allowance to MedicalCV on patent applications pertaining to various aspects of MedicalCV's proprietary laser-based surgical ablation technology. MedicalCV currently markets both the ATRILAZE and SOLAR Surgical Ablation Systems.

Both the SOLAR and ATRILAZE Surgical Ablation Systems were developed from MedicalCV's laser-based technology with the intent to provide surgeons a versatile ablation platform for the creation of lesions in soft and cardiac tissue. The SOLAR System recently received 510(K) clearance from the FDA for soft tissue ablation and the ATRILAZE System has obtained three separate 510(K) clearances for ablation or coagulation of soft tissue, including cardiac tissue.

However, the treatment indication for cardiac arrhythmias is specifically excluded for both systems at this time. To date, the company's surgical ablation systems have been used in numerous institutions around the country including Baylor University Medical Center, Northwestern University Medical Center, University of Michigan Medical Center, Baptist Medical Center in San Antonio, TX, Scottsdale Healthcare - Osborn in Arizona, Banner Good Samaritan Medical Center in Phoenix, and Banner Baywood Heart Hospital in Mesa, AZ.

For more information visit www.medcvinc.com.


Related Content

News

Sept. 8, 2026 — Abbot has announced that it has received U.S. Food and Drug Administration (FDA) approval for the ...

Home September 08, 2026
Home
News

Aug. 31, 2026 — At the European Society of Cardiology Congress in Munich, Abbott announced new late-breaking 12-month ...

Home September 02, 2026
Home
News

July 8, 2026 — Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) approved the Dual Energy ...

Home July 08, 2026
Home
News

May 21, 2026 — Adagio Medical Holdings, a provider of catheter ablation technologies for treating cardiac arrhythmias ...

Home May 22, 2026
Home
News

April 26, 2026 — New results from the multicenter catheter ablation versus anti-arrhythmic drugs for Ventricular ...

Home April 29, 2026
Home
News

April 24, 2026 — Johnson & Johnson recently announced the initiation of the PERSIGMA randomized controlled trial (RCT) ...

Home April 27, 2026
Home
News

April 26, 2026 – New results from the pivotal multicenter trial FULCRUM-VT show that ultra-low temperature ablation ...

Home April 27, 2026
Home
News

April 13, 2026 — Johnson & Johnson has announced favorable 12-month interim effectiveness and safety results from ...

Home April 13, 2026
Home
News

In a milestone for Broward Health in Ft. Lauderdale, Fla., Jose L. Baez-Escudero, M.D., chief of cardiology and ...

Home March 24, 2026
Home
News

Feb. 6, 2026 — Abbott has announced new clinical data from two late-breaking presentations at AF Symposium in Boston ...

Home February 06, 2026
Home
Subscribe Now